2Global Initiative for Chronic Obstructive Pulmonary Disease, Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease[J]. 2006. www. goldcopd. com.
4[1]Global Initiative for Chronic Obstructive Pulmonary Disease.Global strategy for the diagnosis,management and prevention of chronic obstructive pulmonary disease[A/OL].[2006].www.goldcopd.com.
6[5]Wedzicha JA,Seemungal TA.COPD exacerbations:defining their cause and prevention[J].Lancet,2007,370(9589):786-796.
7[6]Gan WQ,Man SF,Sin DD.The interactions between cigarette smoking and reduced lung function on systemic inflammation[J].Chest,2005,127(2):558-564.
8[7]Donaldson GC,Seemungal TA,Bhowmik A,et al.Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease[J].Thorax,2002,57(10):847-852.
9[8]Barnes PJ,Chowdhury B,Kharitonov SA,et al.Pulmonary biomarkers in chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,2006,174(1):6-14.
10[9]Perera WR,Hurst JR,Wilkinson TM,et al.Inflammatory changes,recovery and recurrence at COPD exacerbation[J].Eur Respir J,2007,29(3):527-534.
4Cel li B, Mac Nee W. A TS/E RS Task Force. Standards f or the diagnosis and treatment of patients with COPD : a summary of the ATS/ ERS position paper [ J ]. Eur Respir J, 2004, 23 : 932 - 946.
5Papi A, Romagnoli M, Baraldo S, et al. Partial reversibility of air- flow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease [ J ]. American Journal of Respiratory and Critical Care Medicine, 2000, 162 ( 5 ) : 1 773 - 1 777.
6Cipollone F, Mezzetti A, Porreca E, et al. Association between enhanced soluble CD40L and protlirombotic state in hyperc- holesterolemia: effects of statin therapy[J]. Circulation, 2002, 106 (4) :399 - 402.
7Bircan A, Gokirmak M, Kilic O, et al. C - reactive protein levels in patients with chronic obstructive pulmonary disease: role of in- fection[J]. Med Princ Pract, 2008, 17(3) :202 - 208.
8Agusti A, Faner R. Systemic inflammation and comorbidities in chronic obstructive pulmonary disease[J]. Proc Am Thorae Soc,2012, 9(2) :43 - 46.
9Kwon YS, Chi SY, Shin HJ. Plasma C - reactive protein and en- dothelin- 1 leveA in patients with chronic obstructive pulmonary disease and pulmonary hypertension[J ]. J Korean Med Sei, 2010, 25 (10) : 1487 - 1491.
10ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories.ATS statement:guidelines for the six-minute walk test[].American Journal of Respiratory and Critical Care Medicine.2002
